A Phase I Study of Allogeneic Myocardium-Derived Mesenchymal Stem Cells (HB1011) in Patients With Ischemic Cardiomyopathy

by | Oct 6, 2026 | Clinical Trials | 0 comments

​ Conditions: Ischemic Cardiomyopathy

Interventions: Biological: HB1011 (Allogeneic Myocardium-derived Mesenchymal Stem Cells); Biological: HB1011 (Allogeneic Myocardium-derived Mesenchymal Stem Cells)

Sponsors: HieraBio Inc.

Recruiting Conditions: Ischemic Cardiomyopathy
Interventions: Biological: HB1011 (Allogeneic Myocardium-derived Mesenchymal Stem Cells); Biological: HB1011 (Allogeneic Myocardium-derived Mesenchymal Stem Cells)
Sponsors: HieraBio Inc.
Recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *